May 7, 2013 I Rapid expansion in coverage over the coming years will see the Filipino seasonal influenza vaccine market quadruple in size by 2018, states the latest report from business intelligence providers GBI Research.
According to the firm’s latest healthcare research*, revenue for the Filipino seasonal influenza vaccine market is forecast to rocket from US$107m in 2012 to US$454m in 2018, representing an increase of over 400% in just six years.
Flu vaccine coverage is expected to increase substantially across the country, as the population looks to protect itself from the kind of highly contagious infection that often originates in the densely populated regions of Asia.
GBI Research anticipates the portion of Filipinos vaccinated against seasonal influenza to climb significantly over the forecast period. This is particularly true of young children, with 45% of those aged six months to eight years expected to be vaccinated by 2018, compared to 14% in 2012.
The business intelligence firm believes that seasonal influenza vaccine market growth will be impressive across a number of countries in the Asia-Pacific region. Between 2012 and 2018, industry revenue in both India and Malaysia is estimated to climb at a CAGR of 23%, while in China a CAGR of 15% is forecast.
However, Japan – the most valuable seasonal influenza vaccine market in the region – is expected to increase at a much more modest CAGR of 1.6%, from US$557m last year to US$621m in 2018.
SOURCE: GBI Research
Post Views: 1,503
May 7, 2013 I Rapid expansion in coverage over the coming years will see the Filipino seasonal influenza vaccine market quadruple in size by 2018, states the latest report from business intelligence providers GBI Research.
According to the firm’s latest healthcare research*, revenue for the Filipino seasonal influenza vaccine market is forecast to rocket from US$107m in 2012 to US$454m in 2018, representing an increase of over 400% in just six years.
Flu vaccine coverage is expected to increase substantially across the country, as the population looks to protect itself from the kind of highly contagious infection that often originates in the densely populated regions of Asia.
GBI Research anticipates the portion of Filipinos vaccinated against seasonal influenza to climb significantly over the forecast period. This is particularly true of young children, with 45% of those aged six months to eight years expected to be vaccinated by 2018, compared to 14% in 2012.
The business intelligence firm believes that seasonal influenza vaccine market growth will be impressive across a number of countries in the Asia-Pacific region. Between 2012 and 2018, industry revenue in both India and Malaysia is estimated to climb at a CAGR of 23%, while in China a CAGR of 15% is forecast.
However, Japan – the most valuable seasonal influenza vaccine market in the region – is expected to increase at a much more modest CAGR of 1.6%, from US$557m last year to US$621m in 2018.
SOURCE: GBI Research
Post Views: 1,503
